$116 Million is the total value of Opaleye Management Inc.'s 27 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 70.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CMRX | Buy | CHIMERIX INC | $17,333,000 | +41.6% | 790,000 | +47.4% | 14.94% | +65.3% |
| RTRX | Buy | RETROPHIN INC | $14,281,000 | -41.6% | 1,216,400 | +5.5% | 12.31% | -31.8% |
| ARIA | Sell | ARIAD PHARMACEUTICALS INC | $10,574,000 | -21.4% | 1,660,000 | -0.6% | 9.12% | -8.3% |
| PCYC | Sell | PHARMACYCLICS INC | $8,971,000 | -22.2% | 100,000 | -13.0% | 7.74% | -9.1% |
| GNMK | Buy | GENMARK DIAGNOSTICS INC | $6,765,000 | +56.5% | 500,000 | +14.9% | 5.83% | +82.6% |
| BINDQ | Buy | BIND THERAPEUTICS INC | $6,485,000 | +27.0% | 492,000 | +15.2% | 5.59% | +48.2% |
| NSPR | Buy | INSPIREMD INC | $6,431,000 | -2.0% | 2,180,000 | +1.4% | 5.54% | +14.4% |
| CEMP | Buy | CEMPRA INC | $5,417,000 | -2.3% | 504,800 | +5.2% | 4.67% | +14.1% |
| CLVS | New | CLOVIS ONCOLOGY INC | $5,369,000 | – | 130,000 | +100.0% | 4.63% | – |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $5,269,000 | – | 115,000 | +100.0% | 4.54% | – |
| CSII | CARDIOVASCULAR SYS INC DEL | $4,207,000 | -2.0% | 135,000 | 0.0% | 3.63% | +14.4% | |
| CPRX | CATALYST PHARM PARTNERS INC | $3,488,000 | +11.9% | 1,378,584 | 0.0% | 3.01% | +30.6% | |
| INSYQ | New | INSYS THERAPEUTICS INC NEW | $2,680,000 | – | 85,800 | +100.0% | 2.31% | – |
| TTPH | Buy | TETRAPHASE PHARMACEUTICALS I | $2,289,000 | +30.3% | 169,700 | +6.1% | 1.97% | +52.1% |
| MZOR | New | MAZOR ROBOTICS LTD | $2,108,000 | – | 120,000 | +100.0% | 1.82% | – |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $2,020,000 | – | 45,000 | +100.0% | 1.74% | – |
| EVOK | Buy | EVOKE PHARMA INC | $1,962,000 | +0.3% | 242,500 | +3.9% | 1.69% | +17.1% |
| REPH | New | RECRO PHARMA INC | $1,762,000 | – | 220,000 | +100.0% | 1.52% | – |
| CELGZ | CELGENE CORPright 12/31/2030 | $1,716,000 | -8.8% | 660,000 | 0.0% | 1.48% | +6.6% | |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $1,397,000 | – | 30,000 | +100.0% | 1.20% | – |
| BLRX | Sell | BIOLINERX LTD | $1,352,000 | -58.2% | 650,000 | -55.2% | 1.17% | -51.2% |
| CDXS | Buy | CODEXIS INC | $1,197,000 | -16.0% | 820,000 | +17.4% | 1.03% | -2.0% |
| CPXX | Buy | CELATOR PHARMACEUTICALS INC | $1,073,000 | +4.1% | 338,402 | +4.1% | 0.92% | +21.4% |
| KBIO | Sell | KALOBIOS PHARMACEUTICALS INC | $730,000 | -50.5% | 320,000 | -41.3% | 0.63% | -42.2% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $455,000 | – | 7,200 | +100.0% | 0.39% | – |
| KIPS | Sell | KIPS BAY MED INC | $355,000 | -34.3% | 772,031 | -0.7% | 0.31% | -23.3% |
| PRTA | New | PROTHENA CORP PLC | $295,000 | – | 13,104 | +100.0% | 0.25% | – |
| SSH | Exit | SUNSHINE HEART INC | $0 | – | -60,000 | -100.0% | -0.26% | – |
| AFFX | Exit | AFFYMETRIX INC | $0 | – | -100,000 | -100.0% | -0.53% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -30,000 | -100.0% | -0.62% | – |
| ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -305,000 | -100.0% | -1.06% | – |
| FLXN | Exit | FLEXION THERAPEUTICS INC | $0 | – | -135,500 | -100.0% | -1.65% | – |
| GERN | Exit | GERON CORP | $0 | – | -1,100,000 | -100.0% | -1.70% | – |
| LGND | Exit | LIGAND PHARMACEUTICALS INC | $0 | – | -35,000 | -100.0% | -1.74% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -115,500 | -100.0% | -1.94% | – |
| FLDM | Exit | FLUIDIGM CORP DEL | $0 | – | -90,000 | -100.0% | -2.93% | – |
| NVDQ | Exit | NOVADAQ TECHNOLOGIES INC | $0 | – | -167,600 | -100.0% | -3.04% | – |
| P103PS | Exit | NPS PHARMACEUTICALS INC | $0 | – | -150,000 | -100.0% | -3.32% | – |
| OMER | Exit | OMEROS CORP | $0 | – | -500,100 | -100.0% | -4.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.